|本期目录/Table of Contents|

[1]王欣,柴学峰,王国君.利拉鲁肽对不同体质量指数2型糖尿病合并非酒精性脂肪肝患者的治疗效果[J].慢性病学杂志,2020,21(10):1488-1491.
　WANGXin*,CHAIXue-feng,WANGGuo-jun.Therapeutic effect of liraglutide on patients with different body mass index type2diabetes mellitus complicated with nonalcoholic fatty liver disease[J].,2020,21(10):1488-1491.
点击复制

利拉鲁肽对不同体质量指数2型糖尿病合并非酒精性脂肪肝患者的治疗效果

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
21
期数:
2020年10期
页码:
1488-1491
栏目:
论　著
出版日期:
2020-09-28

文章信息/Info

Title:
Therapeutic effect of liraglutide on patients with different body mass index type2diabetes mellitus complicated with nonalcoholic fatty liver disease
作者:
王欣1; 柴学峰2; 王国君3
1.内蒙古科技大学包头医学院，内蒙古 包头 014000； 2.包头市青山区疾病预防控制中心，内蒙古 包头 014030； 3.内蒙古科技大学包头医学院第二附属医院内分泌科，内蒙古 包头 014030
Author(s):
WANGXin* ; CHAIXue-feng; WANGGuo-jun
*Baotou Medical College ofInnerMongoliaUniversityofScienceandTechnology, Baotou,InnerMongolia014030, China Correspondingauthor:WANGGuo-jun,E-mail:wgj20888@163.com
关键词:
2型糖尿病; 非酒精性脂肪肝; 体质量指数; 肝脏脂肪含量; 利拉鲁肽
Keywords:
Type2 diabetes;  Nonalcoholic fatty liver disease;  Body mass index;  Liver fat content;  Lira-glutide
分类号:
R587.1
DOI:
-
摘要:
目的 探讨利拉鲁肽对不同体质量指数（BMI）2型糖尿病（T2DM）合并非酒精性脂肪肝（NAFLD） 患者的临床治疗效果。方法 选取2017年1月至2019年12月内蒙古科技大学包头医学院第二附属医院内分泌科 收治的100例T2DM合并NAFLD患者作为研究对象，按BMI≥30kg/m 2（A组）和BMI<30kg/m 2（B组）分 为两组，每组50例。均给予利拉鲁肽治疗24周，对治疗前后BMI、胰岛素抵抗指数（HOMA-IR）、糖化血红蛋 白（HbA1c）、空腹血糖（FPG）、血脂及肝脾CT值比值（L/S）结果等进行比较，观察利拉鲁肽对T2DM合并 NAFLD患者的治疗效果。结果 两组治疗后BMI、腰围（WC）、FPG、HbA1c、LnHOMA-IR、甘油三酯 （TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、丙氨酸氨基转移酶（ALT）、谷氨酰转移酶 （GGT）均较治疗前下降，L/S较治疗前升高，差异均有统计学意义（P<0.05）；治疗前后A组差值△BMI、 △WC、△HbA1c、△FPG、△HOMA-IR、△TG、△L/S均高于B组，差异有统计学意义（P<0.05）。结论 利拉鲁肽可有效降糖、降脂、减重，同时可减少T2DM合并NAFLD患者肝脏脂肪含量，有效治疗NAFLD，且 BMI≥30kg/m 2者临床效果更显著。
Abstract:
Objective To explore the clinical effect and value of liraglutide on different body mass index （BMI）patients with type 2 diabetes mellitus（T2DM）and nonalcoholic fatty liver （NAFLD）. Methods Totally100 patients with T2DM complicated with NAFLD were selected and divided into two groups: BMI≥30 kg/m 2 group and BMI<30 kg/m 2 group, 50 cases in each group. All patients were treated with liraglutide for24 weeks. BMI, insulin resistance index（HOMA-IR）, glycosylated hemoglobin（HbA1c）, fasting blood glucose（FPG）, triglycerides（TG）, total cholesterol（TC）, low-density lipoprotein cholesterol（LDL-C）, and liver/spleen CT ratio（L/S）results before and af-ter treatment were compared. Results After treatment, BMI, waist circumference（WC）, FPG, HbA1c, LnHOMA- IR, TG, TC, LDL- C, alanine aminotransferase （ALT）, glutamyltransferase （GGT）in the two groups were all decreased （P<0.05）, and L/S was increased（P<0.05）. Thechanges of BMI, WC, HbA1c, FPG, HOMA-IR, TG, L/S in the BMI≥30 kg/m 2 group were more significant than those in the BMI<30 kg/m 2 group（P<0.05）. Conclusion Liraglutide can effectively reduce liver fat content in T2DM patients complicated with NAFLD while it can effectively reduce blood glucose, lipid and weight, especially in patients with BMI≥30 kg/m

参考文献/References:

[1] Gao H, Xu L, Li D,et al. Effects of glucagon-like pep-tide-1 on liver oxidative stress, TNF-ɑ and TGF-β1 in rats with non-alcoholic fatty liver disease [J]. South Med Univ,2013,33(11):1661-1664. [2] T?lb?l KS, Kristiansen MN, Hansen HH, et al. Metabol-ic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis [J]. World J Gastro-enterol, 2018,24(2):179-194. [3] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪 性肝病诊疗指南(2010年修订版) ［J］.中华肝脏病杂志,2010,18 (3):163-166. [4] Benedict M, Zhang X. Non- alcoholic fatty liver disease: An expanded review [J]. World J Hepatol,2017,9(16):715-732. [5] Yang KC, Hung HF, Lu CW,et al. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome In-dependently of Central Obesity and Insulin Resistance [J]. Sci Rep,2016,6:27034. [6] 叶启宝,何媛媛,吕齐欢,等.利拉鲁肽治疗2型糖尿病合并非酒精 性脂肪肝患者的临床观察[J].医学研究杂志,2015,44(70):152-154. [7] Sumida Y, Seko Y, Yoneda M. Novel antidiabetic medi-cations for non-alcoholic fatty liver disease with type 2 di-abetes mellitus [J]. Hepatol Res, 2017,47(4):266-280. [8] Lee BW, Lee YH, Park CY,et al. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association [J]. Diabetes Metab, 2020,44(3):382-401. [9] Tanase DM, Gosav EM, Costea CF,et al. The Intricate Relationship between Type2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Dis-ease (NAFLD) [J]. Diabetes Res, 2020,2020(8):3920196. [10] Ohki T, Isogawa A, Iwamoto M,et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type2 diabetes mellitus compared to sitagliptin and pioglitazone [J]. Sci World J,2012:496453. [11] Feng WH, Bi Y, Li P,et al. Effects of liraglutide, met-formin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial [J]. Diabetes Investig,2019,10(2):399-407. [12] Tian F, Zheng Z, Zhang D,et al. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease [J]. Biosci Rep, 2018,38(6): BSR20181304. [13] Zhang Z, Qi Y, Kong W,etal. Efficacy and Clinical Val-ue of Liraglutide for Treatment of Diabetes Mellitus Com-plicated by Non- Alcoholic Fatty Liver Disease [J]. Med Sci Monit,2018,24:7399-7404.

备注/Memo

备注/Memo:
基金项目：包头医学院科学研究基金项目（BYJJ-YF201742） 作者简介：王欣，硕士研究生，研究方向：糖尿病与代谢性疾病 通信作者：王国君，E-mail: wgj20888@163.com
更新日期/Last Update: 2020-09-28